Advertisement
APUS vs DERM
Which Stock Would AI Choose? Apimeds Pharmaceuticals US (APUS) vs. Journey Medical (DERM) Stock Comparison
Key Takeaways
- APUS is an early-stage company that has recently pivoted toward digital-asset (bitcoin treasury) operations, while DERM is a commercial-stage dermatology pharmaceutical company with marketed, revenue-generating products.
- DERM generates recurring revenue from eight branded, FDA (U.S. Food and Drug Administration)-approved drugs; APUS reported no biopharmaceutical revenue and disclosed a going-concern risk in its most recent annual filing.
- Sector exposure is sharply different: APUS blends biotechnology with bitcoin and blockchain assets, whereas DERM is concentrated in specialty dermatology healthcare.
- APUS carries elevated financial risk from its thin cash position and recent merger; DERM's risk profile centers on product competition and commercialization execution.
- Relative performance and sentiment are likely driven by broader bitcoin and digital-asset trends for APUS versus specialty-pharma fundamentals for DERM.
Introduction
Investors comparing APUS and DERM are essentially weighing two very different risk profiles within the small-cap universe. One is an emerging digital-asset and biotechnology venture, while the other is a commercial-stage pharmaceutical company with established revenue. This stock comparison is most relevant to traders and investors assessing market positioning, growth catalysts, and relative performance across contrasting industries. Understanding how each company's business model, financial health, and recent momentum interact can help clarify which name may better align with a given risk tolerance or portfolio objective.
APUS Overview and Recent Performance
Apimeds Pharmaceuticals US, Inc. (APUS), listed on NYSE American, has transitioned toward providing digital-asset treasury solutions focused on bitcoin treasury infrastructure. Following a merger completed in late 2025, the company now operates across two segments: a biopharmaceutical arm advancing a clinical-stage candidate and a digital-asset operations arm tied to blockchain holdings. APUS is a subsidiary of South Korea-based Inscobee, Inc.
Recent market activity has reflected the company's early-stage, pre-revenue profile. In its latest annual filing, APUS reported no biopharmaceutical revenue and disclosed a net loss, a limited cash position, and a going-concern warning. These factors, combined with its exposure to the volatility of bitcoin and related digital assets, have shaped sentiment. As a result, APUS's stock behavior is more closely linked to cryptocurrency market swings and restructuring milestones than to traditional operational fundamentals.
DERM Overview and Recent Performance
Journey Medical Corporation (DERM) is a commercial-stage pharmaceutical company based in Scottsdale, Arizona, focused on developing and marketing FDA-approved prescription treatments for dermatological conditions. The company currently markets eight branded products and was founded by Fortress Biotech, Inc.
DERM reported its full-year 2025 financial results and recent corporate highlights, followed by first-quarter 2026 results, underscoring a steady cadence of operational disclosures. Recent weeks have been shaped by the company's commercialization progress, product portfolio execution, and participation in healthcare investor conferences. Unlike APUS, DERM has a tangible revenue base and a sales-and-marketing infrastructure, which tends to produce more fundamentally driven price behavior. Its sentiment is influenced by prescription trends, competitive dynamics in dermatology, and the pace of any pipeline or business-development activity.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, statistics, and set of covered tickers. Because not every bot fits every market regime, Tickeron curates a dedicated Trending AI Robots section to highlight only the bots best suited to current market conditions. This selective approach helps traders filter through a large, diverse bot universe to find strategies that are performing well right now. Whether you are comparing names like APUS and DERM or scanning broader opportunities, exploring the Trending AI Robots page can be a practical way to see which automated strategies are currently in favor.
Head-to-Head Comparison
Across key dimensions, these two companies represent opposing investment theses. In terms of business model, DERM is a revenue-generating specialty pharmaceutical company, while APUS is a pre-revenue entity repositioning around bitcoin treasury infrastructure. Their growth drivers also differ: DERM relies on prescription volume, product expansion, and potential licensing deals, whereas APUS depends on digital-asset appreciation, blockchain adoption, and the future progress of a clinical-stage candidate.
On recent momentum, APUS is more sensitive to cryptocurrency sentiment, which can swing sharply in either direction, while DERM's moves are more anchored to earnings and commercialization news. Risk factors are equally distinct. APUS faces liquidity constraints and a disclosed going-concern risk, whereas DERM faces competitive and market-access risks common to specialty pharma but benefits from an established revenue stream. These contrasts make the pair a useful illustration of how market positioning and sector exposure can diverge even among smaller-cap stocks.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and the presence of durable catalysts, Tickeron's AI would likely favor DERM in the current environment. DERM's recurring revenue, established product portfolio, and more fundamentally driven price action tend to produce steadier, more identifiable trends than APUS's reliance on early-stage restructuring and volatile digital-asset exposure. APUS's exposure to bitcoin could offer substantial upside under favorable market conditions, but its thin cash position and going-concern disclosure introduce elevated uncertainty. Accordingly, an AI-driven assessment would lean toward DERM on a relative basis, while acknowledging that APUS remains a higher-risk, higher-uncertainty profile that may appeal to a different segment of traders.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APUS is a Hold and DERM is a Hold.
APUS sees MACD Histogram just turned negative
APUS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 15, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 13 instances where the indicator turned negative. In 13 of the 13 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for APUS moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In 5 of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APUS as a result. In 24 of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
APUS moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
APUS broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for APUS crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +121.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where APUS advanced for three days, in 44 of 49 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 31 of 35 cases where APUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.045) is normal, around the industry mean (10.407). P/E Ratio (-0.088) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. APUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
DERM in downward trend: price dove below 50-day moving average on September 23, 2026
DERM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 51 of 56 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DERM as a result. In 82 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 10-day moving average for DERM crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DERM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for DERM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DERM's RSI Oscillator exited the oversold zone, 25 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where DERM advanced for three days, in 231 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
DERM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.474) is normal, around the industry mean (10.407). P/E Ratio (-23.136) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.865) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. DERM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DERM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
DERM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 82 | |
P/E GROWTH RATING 1..100 | 17 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| APUS | DERM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 90% | N/A |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| Advances ODDS (%) | 18 days ago 90% | 4 days ago 85% |
| Declines ODDS (%) | 2 days ago 90% | 8 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APUS’s FA Score shows that 2 FA rating(s) are green while DERM’s FA Score has 2 green FA rating(s).
- APUS’s FA Score: 2 green, 3 red.
- DERM’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APUS’s TA Score shows that 4 TA indicator(s) are bullish while DERM’s TA Score has 4 bullish TA indicator(s).
- APUS’s TA Score: 4 bullish, 6 bearish.
- DERM’s TA Score: 4 bullish, 5 bearish.
Price Growth
APUS (@Pharmaceuticals: Generic) experienced а -28.02% price change this week, while DERM (@Pharmaceuticals: Generic) price change was -0.68% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.61%. For the same industry, the average monthly price growth was -10.62%, and the average quarterly price growth was +7.80%.
Reported Earning Dates
APUS is expected to report earnings on Nov 11, 2026.
DERM is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.61% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
APUS and
Correlation & Price change
A.I.dvisor indicates that over the last year, APUS has been loosely correlated with DERM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if APUS jumps, then DERM could also see price increases.
| Ticker / NAME | Correlation To APUS | 1D Price Change % | ||
|---|---|---|---|---|
| APUS | 100% | -2.77% | ||
| DERM - APUS | 49% Loosely correlated | +6.04% | ||
| SNOA - APUS | 41% Loosely correlated | N/A | ||
| ACB - APUS | 24% Poorly correlated | +0.25% | ||
| PAHC - APUS | 21% Poorly correlated | +1.43% | ||
| TRLV - APUS | 11% Poorly correlated | -0.73% | ||
More | ||||